Howe & Rusling Inc. Boosts Position in Becton, Dickinson and Company $BDX

Key Points

• Howe & Rusling Inc. increased its stake in Becton, Dickinson and Company by 15.2% during the 1st quarter, bringing the total shares owned to 27,890, valued at approximately $6.39 million.
• Several institutional investors have recently made changes to their holdings, with 86.97% of the company's stock now owned by hedge funds and other large investors.
• Following a solid earnings report, Becton, Dickinson and Company reported a net margin of 7.51% and raised its FY 2025 EPS guidance to a range of 14.300-14.450.

Howe & Rusling Inc. lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 15.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 27,890 shares of the medical instruments supplier's stock after acquiring an additional 3,688 shares during the period. Howe & Rusling Inc.'s holdings in Becton, Dickinson and Company were worth $6,388,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of BDX. Saudi Central Bank purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter worth $26,000. Smallwood Wealth Investment Management LLC purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter worth $27,000. REAP Financial Group LLC raised its holdings in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares during the period. Alpine Bank Wealth Management purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter worth $29,000. Finally, Cornerstone Planning Group LLC raised its holdings in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 99 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the business's stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company's stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,965 shares of company stock worth $551,536 over the last quarter. Insiders own 0.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BDX. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Barclays reduced their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Piper Sandler restated a "neutral" rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price objective for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Four analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of "Hold" and an average price target of $211.44.

Becton, Dickinson and Company Stock Up 1.1%

Shares of NYSE:BDX opened at $190.52 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a market capitalization of $54.61 billion, a PE ratio of 34.27, a price-to-earnings-growth ratio of 1.41 and a beta of 0.27. The firm's 50-day moving average is $186.24 and its two-hundred day moving average is $192.03. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.